...
iova-img

Iovance Biotherapeutics Inc, Common Stock

IOVA

NMQ

$7.46

+$0.08

(1.08%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.20B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
7.28M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.59
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.7 L
$18.33 H
$7.46

About Iovance Biotherapeutics Inc, Common Stock

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIOVASectorS&P500
1-Week Return-4.85%-0.94%-2.6%
1-Month Return-19.53%-5.08%-1.08%
3-Month Return-22.77%-10.62%3.45%
6-Month Return-8.58%-6.18%8.57%
1-Year Return-16.09%1.98%24.3%
3-Year Return-63%-0.93%25.58%
5-Year Return-74.15%33.84%84.07%
10-Year Return-6.75%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue---238.00K1.19M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":20.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue8.12M8.71M13.98M21.14M10.76M[{"date":"2019-12-31","value":38.43,"profit":true},{"date":"2020-12-31","value":41.22,"profit":true},{"date":"2021-12-31","value":66.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.89,"profit":true}]
Gross Profit(8.12M)(8.71M)(13.98M)(21.14M)(9.57M)[{"date":"2019-12-31","value":-812299900,"profit":false},{"date":"2020-12-31","value":-871200000,"profit":false},{"date":"2021-12-31","value":-1398000000,"profit":false},{"date":"2022-12-31","value":-2113500000,"profit":false},{"date":"2023-12-31","value":-956600000,"profit":false}]
Gross Margin---(8880.25%)(804.54%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-8880.25,"profit":false},{"date":"2023-12-31","value":-804.54,"profit":false}]
Operating Expenses206.87M261.94M342.70M398.88M450.99M[{"date":"2019-12-31","value":45.87,"profit":true},{"date":"2020-12-31","value":58.08,"profit":true},{"date":"2021-12-31","value":75.99,"profit":true},{"date":"2022-12-31","value":88.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(206.87M)(261.94M)(342.70M)(398.88M)(460.56M)[{"date":"2019-12-31","value":-20687200000,"profit":false},{"date":"2020-12-31","value":-26193700000,"profit":false},{"date":"2021-12-31","value":-34270300000,"profit":false},{"date":"2022-12-31","value":-39887800000,"profit":false},{"date":"2023-12-31","value":-46055900000,"profit":false}]
Total Non-Operating Income/Expense18.63M4.71M902.00K5.97M24.68M[{"date":"2019-12-31","value":75.48,"profit":true},{"date":"2020-12-31","value":19.09,"profit":true},{"date":"2021-12-31","value":3.65,"profit":true},{"date":"2022-12-31","value":24.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(197.56M)(259.58M)(342.25M)(395.89M)(447.52M)[{"date":"2019-12-31","value":-19755600000,"profit":false},{"date":"2020-12-31","value":-25958100000,"profit":false},{"date":"2021-12-31","value":-34225200000,"profit":false},{"date":"2022-12-31","value":-39589300000,"profit":false},{"date":"2023-12-31","value":-44751600000,"profit":false}]
Income Taxes(10.48M)(2.36M)(14.43M)(5.97M)(3.48M)[{"date":"2019-12-31","value":-1048500000,"profit":false},{"date":"2020-12-31","value":-235600000,"profit":false},{"date":"2021-12-31","value":-1443100000,"profit":false},{"date":"2022-12-31","value":-597000000,"profit":false},{"date":"2023-12-31","value":-347900000,"profit":false}]
Income After Taxes(187.07M)(257.23M)(327.82M)(389.92M)(444.04M)[{"date":"2019-12-31","value":-18707100000,"profit":false},{"date":"2020-12-31","value":-25722500000,"profit":false},{"date":"2021-12-31","value":-32782100000,"profit":false},{"date":"2022-12-31","value":-38992300000,"profit":false},{"date":"2023-12-31","value":-44403700000,"profit":false}]
Income From Continuous Operations(197.56M)(259.58M)(342.25M)(395.89M)(432.98M)[{"date":"2019-12-31","value":-19755600000,"profit":false},{"date":"2020-12-31","value":-25958100000,"profit":false},{"date":"2021-12-31","value":-34225200000,"profit":false},{"date":"2022-12-31","value":-39589300000,"profit":false},{"date":"2023-12-31","value":-43297700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(187.07M)(257.23M)(327.82M)(389.92M)(444.04M)[{"date":"2019-12-31","value":-18707100000,"profit":false},{"date":"2020-12-31","value":-25722500000,"profit":false},{"date":"2021-12-31","value":-32782100000,"profit":false},{"date":"2022-12-31","value":-38992300000,"profit":false},{"date":"2023-12-31","value":-44403700000,"profit":false}]
EPS (Diluted)(1.58)(1.89)(2.22)(2.48)(1.88)[{"date":"2019-12-31","value":-158,"profit":false},{"date":"2020-12-31","value":-189,"profit":false},{"date":"2021-12-31","value":-222,"profit":false},{"date":"2022-12-31","value":-248,"profit":false},{"date":"2023-12-31","value":-188,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IOVA
Cash Ratio 3.37
Current Ratio 4.22
Quick Ratio 3.90

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IOVA
ROA (LTM) -29.16%
ROE (LTM) -56.65%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IOVA
Debt Ratio Lower is generally better. Negative is bad. 0.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.78

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IOVA
Trailing PE NM
Forward PE NM
P/S (TTM) 24.76
P/B 2.91
Price/FCF NM
EV/R 21.25
EV/Ebitda NM
PEG NM

FAQs

What is Iovance Biotherapeutics Inc share price today?

Iovance Biotherapeutics Inc (IOVA) share price today is $7.46

Can Indians buy Iovance Biotherapeutics Inc shares?

Yes, Indians can buy shares of Iovance Biotherapeutics Inc (IOVA) on Vested. To buy Iovance Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IOVA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Iovance Biotherapeutics Inc be purchased?

Yes, you can purchase fractional shares of Iovance Biotherapeutics Inc (IOVA) via the Vested app. You can start investing in Iovance Biotherapeutics Inc (IOVA) with a minimum investment of $1.

How to invest in Iovance Biotherapeutics Inc shares from India?

You can invest in shares of Iovance Biotherapeutics Inc (IOVA) via Vested in three simple steps:

  • Click on Sign Up or Invest in IOVA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Iovance Biotherapeutics Inc shares
What is Iovance Biotherapeutics Inc 52-week high and low stock price?

The 52-week high price of Iovance Biotherapeutics Inc (IOVA) is $18.33. The 52-week low price of Iovance Biotherapeutics Inc (IOVA) is $6.7.

What is Iovance Biotherapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Iovance Biotherapeutics Inc (IOVA) is

What is Iovance Biotherapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Iovance Biotherapeutics Inc (IOVA) is 2.91

What is Iovance Biotherapeutics Inc dividend yield?

The dividend yield of Iovance Biotherapeutics Inc (IOVA) is 0.00%

What is the Market Cap of Iovance Biotherapeutics Inc?

The market capitalization of Iovance Biotherapeutics Inc (IOVA) is $2.20B

What is Iovance Biotherapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Iovance Biotherapeutics Inc is IOVA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top